Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$9.23
-0.4%
$7.87
$5.01
$18.71
$55.26M0.18117,699 shs35,334 shs
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$9.12
+1.4%
$8.67
$6.60
$14.60
$2.13B1.362,676 shs8,417 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$148.90
+3.9%
$136.50
$122.80
$219.34
$4.14B0.67286,959 shs538,250 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$10.51
+0.6%
$11.24
$5.78
$22.00
$1.34B2.39277,225 shs174,166 shs
Avita Medical Inc. stock logo
RCEL
Avita Medical
$5.63
+0.4%
$6.27
$4.71
$14.16
$148.30M1.52189,391 shs356,160 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-0.43%+11.88%-0.32%+74.15%+13.95%
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
+1.39%+3.28%-0.38%+27.20%+1.79%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+3.88%+5.34%+9.42%-7.31%-23.09%
Mesoblast Limited stock logo
MESO
Mesoblast
+0.57%-3.22%-11.31%+1.06%+38.38%
Avita Medical Inc. stock logo
RCEL
Avita Medical
+0.36%+8.90%-7.86%-34.76%-33.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.0946 of 5 stars
3.33.00.04.70.62.50.6
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/AN/AN/AN/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
4.491 of 5 stars
3.51.00.04.72.22.51.9
Mesoblast Limited stock logo
MESO
Mesoblast
1.9434 of 5 stars
3.51.00.00.02.40.80.6
Avita Medical Inc. stock logo
RCEL
Avita Medical
0.8502 of 5 stars
3.40.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.57
Moderate Buy$17.7592.31% Upside
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
0.00
N/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$211.1341.79% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
3.00
Buy$18.0071.27% Upside
Avita Medical Inc. stock logo
RCEL
Avita Medical
2.75
Moderate Buy$16.50193.07% Upside

Current Analyst Ratings Breakdown

Latest ATRA, RCEL, BVNRY, MESO, and KRYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
6/24/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00
6/6/2025
Avita Medical Inc. stock logo
RCEL
Avita Medical
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00
5/16/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$195.00 ➝ $189.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$219.00 ➝ $219.00
5/6/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00 ➝ $240.00
4/28/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$221.00 ➝ $240.00
4/10/2025
Avita Medical Inc. stock logo
RCEL
Avita Medical
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$128.94M0.43N/AN/A($16.89) per share-0.55
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$829.12M2.60$1.03 per share8.88$6.99 per share1.30
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$290.52M14.81$4.82 per share30.91$32.90 per share4.53
Mesoblast Limited stock logo
MESO
Mesoblast
$5.90M227.62N/AN/A$4.21 per share2.50
Avita Medical Inc. stock logo
RCEL
Avita Medical
$71.66M2.08N/AN/A$0.17 per share33.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$143.26M$0.8011.408.69N/A21.11%11.89%9.32%8/28/2025 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$89.16M$4.1635.7914.77N/A37.17%14.64%13.28%8/4/2025 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Avita Medical Inc. stock logo
RCEL
Avita Medical
-$61.85M-$2.19N/AN/AN/A-79.61%-632.62%-71.72%8/6/2025 (Estimated)

Latest ATRA, RCEL, BVNRY, MESO, and KRYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.20N/AN/AN/A$95.42 millionN/A
5/15/2025Q1 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million
5/9/2025Q1 2025
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A$0.13N/A$0.13N/A$189.89 million
5/8/2025Q1 2025
Avita Medical Inc. stock logo
RCEL
Avita Medical
-$0.39-$0.53-$0.14-$0.53$33.15 million$18.51 million
5/6/2025Q1 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.38$1.20-$0.18$1.20$98.66 million$88.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
Avita Medical Inc. stock logo
RCEL
Avita Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
0.57
0.57
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
2.81
1.44
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.65
9.27
Mesoblast Limited stock logo
MESO
Mesoblast
0.22
0.96
0.63
Avita Medical Inc. stock logo
RCEL
Avita Medical
9.39
2.09
1.72

Institutional Ownership

CompanyInstitutional Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
Avita Medical Inc. stock logo
RCEL
Avita Medical
27.66%

Insider Ownership

CompanyInsider Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.00%
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.70%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
Avita Medical Inc. stock logo
RCEL
Avita Medical
2.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3305.96 million5.72 millionOptionable
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
1,611236.57 millionN/ANot Optionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21028.90 million24.94 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
80127.78 million103.76 millionOptionable
Avita Medical Inc. stock logo
RCEL
Avita Medical
13026.44 million25.70 millionOptionable

Recent News About These Companies

AVITA Medical, Inc. (RCEL) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$9.23 -0.04 (-0.43%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$9.07 -0.16 (-1.68%)
As of 07/9/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Bavarian Nordic stock logo

Bavarian Nordic OTCMKTS:BVNRY

$9.12 +0.13 (+1.39%)
As of 07/9/2025 11:46 AM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$148.90 +5.56 (+3.88%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$148.92 +0.01 (+0.01%)
As of 05:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$10.51 +0.06 (+0.57%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$10.58 +0.08 (+0.71%)
As of 07/9/2025 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Avita Medical stock logo

Avita Medical NASDAQ:RCEL

$5.63 +0.02 (+0.36%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$5.62 0.00 (-0.09%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.